Primary Prophylaxis for Cryptococcal Meningitis and Impact on Mortality in HIV: A Systematic Review and Meta-Analysis

• Chariyalertsak S , SirisanthanaT, SaengwonloeyO, NelsonK. Clinical presentation and risk behaviors of patients with acquired immunodeficiency syndrome in Thailand, 1994–1998: regional variation and temporal trends. Clin. Infect. Dis.32 , 955–962 (2001).
   PubMed Web of Science ®Google Scholar
• Tihana B , ThomasSH. Cryptococcal meningitis. Br. Med. Bull.72(1) , 99–118 (2004).
   PubMed Web of Science ®Google Scholar
• French N , GrayK, WatreaC et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 16 , 1031–1038 (2002).
   PubMed Web of Science ®Google Scholar
• Okongo M , MorganD, MayanjaB, RossA, WhitworthJ. Causes of death in a rural, population-based human immunodeficiency virus type 1 natural history cohort in Uganda. Int. J. Epidemiol.27 , 698–702 (1998).
   PubMed Web of Science ®Google Scholar
• Casadevall A , SteenbergenJN, NosanchukJD. ‘Readymade‘ virulence and ‘dual use‘ virulence factors in pathogenic environmental fungi – the Cryptococcus neoformans paradigm. Curr. Opin. Microbiol.6 , 332–337 (2003).
   PubMed Web of Science ®Google Scholar
• Chang LW , PhippsWT, KennedyGE, RutherfordGW. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database Syst. Rev. (3) , CD004773 (2005).
   PubMedGoogle Scholar
• Perfect JR , DismukesWE, DromerF et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50(3) , 291–322 (2010).
   PubMed Web of Science ®Google Scholar
• Mocroft A , KatlamaC, JohnsonAM et al. AIDS across Europe, 1994–98: the EuroSIDA study. Lancet 356 , 291–296 (2000).
   PubMed Web of Science ®Google Scholar
• Kovacs JA , MasurH. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N. Engl. J. Med.342 , 1416–1429 (2000).
   PubMed Web of Science ®Google Scholar
• Micol R , TajahmadyA, LortholaryO et al. Cost–effectiveness of primary prophylaxis of AIDS associated cryptococcosis in Cambodia. PLoS ONE 5(11) , e13856 (2010).
   PubMed Web of Science ®Google Scholar
• Meya D , ManabeY, CastelnuovoB et al. Cost–effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or 100 cells/microL who start HIV therapy in resource-limited settings. Clin. Infect. Dis. 51 , 448–455 (2010).
   PubMed Web of Science ®Google Scholar
• Parkes-Ratanshi R , WakehamK, LevinJ et al. Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial. Lancet 11(12) , 933–941 (2011).
   Web of Science ®Google Scholar
• Wanyenze RK , KamyaMR, FatchR et al. Missed opportunities for HIV testing and late stage diagnosis among HIV-infected patients in Uganda. PLoS ONE 6(7) , e21794 (2011).
   PubMed Web of Science ®Google Scholar
• Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. Higgins JPT, Green S (Eds). John Wiley & Sons, Ltd, UK.
   Google Scholar
• Schulz KF , GrimesDA. Allocation concealment in randomized trials: defending against deciphering. Lancet359(9306) , 614–618 (2002).
   PubMed Web of Science ®Google Scholar
• Jadad AR , MooreRA, CarollD et al. Assessing the quality of reports on randomized clinical trials: is blinding necessary? Control. Clin. Trials 17(1) , 1–12 (1996).
   PubMedGoogle Scholar
• Wacholder S , McLaughlinJK, SilvermanDT, MandelJS. Selection of controls in case control studies. Am. J. Epidemiol.135 , 1019–1028 (1992).
   PubMed Web of Science ®Google Scholar
• Rothman KJ , GreenlandS. Meta-analysis. In: Modern Epidemiology. Rothman KJ, Greenland S (Eds). Lippincott-Raven Publishers, PA, USA, 643–673 (1998).
   Google Scholar
• DerSimonian R , LairdN. Meta-analysis in clinical trials. Control. Clin. Trials7 , 177–188 (1986).
   PubMedGoogle Scholar
• Petitti D . Statistical methods in meta-analysis. In: Meta-Analysis, Decision Analysis and Cost–Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine. Oxford University Press, NY, USA, 7.1–7.8 (1994).
   Google Scholar
• Shore RE , GardnerMJ, PannettB. Ethylene oxide: an assessment of the epidemiological evidence on carcinogenicity. Br. J. Ind. Med.50 , 971–997 (1993).
   PubMedGoogle Scholar
• Light RJ , PillemarDB. Quantitative procedures. In: Summing Up: the Science of Reviewing Research. Havard University Press, MA, USA, 50–103 (1984).
   Google Scholar
• Egger M , SmithGD, SchneiderM, MinderC. Bias in meta-analysis detected by a simple graphical test. Br. Med. J.315 , 629–634 (1997).
   PubMed Web of Science ®Google Scholar
• Begg CB , MazumdarM. Publication bias. In: Handbook of Research Synthesis. Cooper H, Hedges LV (Eds). Russell Sage Foundation, NY, USA, 399–409 (1994).
   Google Scholar
• Liberati A , AltmanDG, TetzlaffJ et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339 , b2700 (2009).
   PubMed Web of Science ®Google Scholar
• Chetchotisakd P , SungkanuparphS, ThinkhamropB, MootsikapunP, BoonyaprawitP. A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency. HIV Med.5 , 140–143 (2004).
   PubMed Web of Science ®Google Scholar
• Chariyalertsak S , SupparatpinyoK, SirisanthanaT, NelsonKE. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin. Infect. Dis.34 , 277–284 (2002).
   PubMed Web of Science ®Google Scholar
• Smith DE , BellJ, JohnsonM et al. A randomized, double-blind, placebo-controlled study of itraconazole capsules for the prevention of deep fungal infections in immunodeficient patients with HIV infection. HIV Med. 2 , 78–83 (2001).
   PubMedGoogle Scholar
• McKinsey DS , WheatLJ, CloudGA et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin. Infect. Dis. 28 , 1049–1056 (1999).
   PubMed Web of Science ®Google Scholar
• Cantey PT , StephensDS, RimlandD. Prevention of cryptococcosis in HIV-infected patients with limited access to highly active antiretroviral therapy: evidence for primary azole prophylaxis. HIV Med.6 , 253–259 (2005).
   PubMed Web of Science ®Google Scholar
• Kris AK , MooreR, ChaissonR. Risk factors for cryptococcal meningitis in HIV-infected patients. AIDS Res. Hum. Retroviruses7 , 625–631 (1999).
   Google Scholar
• Quagliarello VJ , ViscoliC, HorwitzRI. Primary prevention of cryptococcal meningitis by fluconazole in HIV-infected patients. Lancet345 , 548–552 (1995).
   PubMed Web of Science ®Google Scholar
• Nightingale SD , CalSX, PetersonDM et al. Primary prophylaxis with fluconazole against systemic fungal infections in HIV-positive patients. AIDS 6 , 191–194 (1992).
   PubMed Web of Science ®Google Scholar
• Ammassari A , LinzaloneA, MurriR, MarascaG, MoraceG, AntinoriA. Fluconazole for the primary prophylaxis of AIDS-associated cryptococcosis: a case–control study. Scand. J. Infect. Dis.27(3) , 235–237 (1995).
   PubMed Web of Science ®Google Scholar
• Newton JA Jr, Tasker SA, Bone WA et al. Weekly fluconazole for the suppression of recurrent thrush in HIV-seropositive patients: impact on the incidence of disseminated cryptococcal infection. AIDS9(11) , 1286–1287 (1995).
   PubMed Web of Science ®Google Scholar
• Manfredi R , AntonioM, OlgaC et al. Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection. Arch. Intern. Med. 157 , 64–69 (1997).
   PubMed Web of Science ®Google Scholar
• Pradier C , BernardE, LubickC et al. Does fluconazole prevent cryptococcal meningitis in human immunodeficiency virus-infected patients? J. Infect. Dis. 165 , 787 (1992).
   PubMed Web of Science ®Google Scholar
• Caputi R , MarstonB, SiegelB, SteinbergJ. Use of azole drugs to prevent cryptococcal infection in patients with AIDS. Presented at: 33rd Inter-Science Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA, USA, 17–30 October 1993.
   Google Scholar
• Nelson MR , FisherM, CartledgeJ, RogersT, GazzardBG. The role of azoles in the treatment and prophylaxis of cryptococcal disease in HIV infection. AIDS8(5) , 651–654 (1994).
   PubMed Web of Science ®Google Scholar
• Powderly WG , FinkelsteinD, FeinbergJ et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N. Engl. J. Med. 332 , 700–705 (1995).
   PubMed Web of Science ®Google Scholar
• Havlir DV , DubeMP, McCutchanJA et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin. Infect. Dis. 27 , 1369–1375 (1998).
   PubMed Web of Science ®Google Scholar
• Nina S , BarnishM, BermanS et al. Low dose fluconazole as primary prophylaxis for cryptococcal infection in AIDS patients with CD4 cell counts of less than 100/mm3; demonstration of efficacy in a prospective, multicentre trial. Clin. Infect. Dis. 23 , 1282–1286 (1996).
   PubMed Web of Science ®Google Scholar
• Bozzette SA , LarsenRA, ChiuJ et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N. Engl. J. Med. 324(9) , 580–584 (1991).
   PubMed Web of Science ®Google Scholar
• Meyer A , KendiCL, PennerCK et al. The impact of routine cryptococcal antigen screening on survival among HIV-infected individuals with advanced immunosuppression in Kenya. Trop. Med. Int. Health 18(4) , 495–503 (2013).
   PubMed Web of Science ®Google Scholar
• Kaplan JE , BensonC, HolmesKH, BrooksJT, PauA, Masur H; Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm. Rep.58 , 1–207 (2009).
   PubMedGoogle Scholar
• Anglaret X , CheneG, AttiaA et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d‘Ivoire: a randomised trial. Lancet 353 , 1463–1468 (1999).
   PubMed Web of Science ®Google Scholar
• Nunn AJ , MwabaP, ChintuC, MwingaA, DarbyshireJH, ZumlaA. Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ337 , a257 (2008).
   PubMedGoogle Scholar
• Wiktor SZ , Sassan-MorokroM, GrantAD et al. Efficacy of trimethoprim–sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d‘Ivoire: a randomised controlled trial. Lancet 353 , 1469–1475 (1999).
   PubMed Web of Science ®Google Scholar
• Tuli K , ClarkT, NingsanondP et al. Primary prophylaxis against fungal infections among persons living with AIDS in Thailand: a cost effectiveness analysis. Presented at: 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 10–14 February 2003.
   Google Scholar
• Lortholary O , PoizatG, ZellerV et al. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS 20 , 2183–2191 (2006).
   PubMed Web of Science ®Google Scholar
• van der Horst CM , SaagMS, CloudGA et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N. Engl. J. Med. 337 , 15–21 (1997).
   PubMed Web of Science ®Google Scholar
• Robinson PA , BauerM, LealME et al. Early mycological treatment failure in AIDS associated cryptococcal meningitis. Clin. Infect. Dis. 28 , 82–92 (1999).
   PubMed Web of Science ®Google Scholar
• Denning DW , ArmstrongRW, LewisBH, StevensDA. Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency. Am. J. Med.91 , 267–272 (1991).
   PubMed Web of Science ®Google Scholar
• Kambugu A , MeyaDB, RheinJ et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin. Infect. Dis. 46(11) , 1694–1701 (2008).
   PubMed Web of Science ®Google Scholar

Websites

• CDC. Fungal diseases – Cryptococcus neoformans cryptococcosis. www.cdc.gov/fungal/cryptococcosis-neoformans (Accessed 10November2012)
   Google Scholar
• WHO. Rapid advice: diagnosis, management and prevention of cryptococcal disease in HIV-infected adults, adolescents and children (2011). www.who.int/hiv/pub/cryptococcal_disease2011/en (Accessed 10November2012)
   Google Scholar
• WHO. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach: 2010 revision. www.who.int/hiv/pub/arv/adult2010/en/index.html (Accessed 11November2012)
   Google Scholar
• Wells GA, Shea B, O‘Connell D et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. www.ohri.ca/programs/clinical_epidemiology/oxford.htm (Accessed 10November2012)
   Google Scholar